Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine April 2020, 61 (4) 10A;
  • Article
  • Info & Metrics
  • PDF
Loading

Discussions with leaders: JNM editor-in-chief Johannes Czernin, with Thomas Hope, continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with John J. Sunderland, PhD, MBA, about advancing 68GA-DOTATOC through the FDA.

Page 477

The academic NDA: Sunderland outlines the story of the 68Ga-DOTATOC new drug application process, including clinical trials, structured content of the NDA document, and associated first-hand experiences from the University of Iowa.

Page 480

Introduction to radiomics: Mayerhoefer and colleagues provide an educational overview of standard radiomics workflow, the basic concepts of radiomic feature classes, and common limitations and pitfalls in radiomics studies.

Page 488

Travel after 177Lu-DOTATATE: Kendi and colleagues look at challenges to gastroenteropancreatic neuroendocrine tumor patients whose residual radiation after 177Lu-labeled DOTATATE treatment sets off alarms at U.S. borders and points of entry.

Page 496

PET tracer accuracy in gliomas: de Zwart and colleagues detail the results of a systematic review and metaanalysis comparing the diagnostic accuracies of different PET tracers in differentiating tumor progression from treatment-related changes in patients with high-grade gliomas.

Page 498

18F-FET PET in recurrent glioma: Maurer and colleagues investigate the effectiveness of 18F-FET PET imaging in differentiating glioma progression from treatment-related changes.

Page 505

89Zr-Df-IAB22M2C anti-CD8 minibody PET: Pandit-Taskar and colleagues report on first-in-human studies of the safety of this radiolabeled minibody against CD8+ T cells for imaging of these cells in patients with cancer.

Page 512

177Lu-PP-F11N for radionuclide therapy: Rottenburger and colleagues determine, using advanced 3-dimensional dosimetry in a first-in-human study, whether this minigastrin analog with therapeutic properties and a γ-ray component for imaging is a suitable agent for treatment of medullary thyroid carcinoma.

Page 520

18F- versus 68Ga-PSMA imaging: Kuten and colleagues compare the diagnostic accuracy of 18F-PSMA-1007 with that of 68Ga-PSMA-11 PET/CT in the same group of patients with newly diagnosed intermediate- or high-risk prostate cancer.

Page 527

Interpretation criteria for 68Ga-PSMA-11 PET: Toriihara and colleagues compare interreader, intrareader, and intercriteria agreement in 3 recently introduced international criteria for interpretation of 68Ga–prostate-specific membrane antigen-11 PET data in prostate cancer.

Page 533

PSMA PET/CT and biopsy for LN staging: Hinsenveld and colleagues determine the diagnostic capabilities of combined prostate-specific membrane antigen PET/CT and sentinel node biopsy in PSMA PET/CT–negative patients for primary lymph node staging in prostate cancer.

Page 540

18F-DCFPyL PET/CT in prostate cancer: Song and colleagues present their institutional experience assessing the positivity rate of PET/CT with this prostate-specific membrane antigen–targeting agent in patients with biochemical recurrence of prostate cancer.

Page 546

Imaging AUC in BCR prostate cancer: Jadvar and members of a multiorganizational workgroup provide a consensus document on the appropriate use of imaging in diagnostic evaluation of patients with biochemical recurrence of prostate cancer after definitive primary treatment.

Page 552

Theranostics targeting FAP: Watabe and colleagues use 64Cu and 225Ac, with long half-lives, to label fibroblast activation protein inhibitors in mice with human pancreatic cancer xenografts to assess the potential of α-therapy targeting FAP in cancer stroma.

Page 563

Imaging β-cell mass with 11C-(+)-PHNO: Bini and colleagues describe pancreatic PET imaging parameters with this dopamine D2 and D3 receptor agonist to differentiate healthy controls from individuals with type 1 diabetes mellitus.

Page 570

18F-Fluorocholine in PHPT: Cuderman and colleagues compare the efficiency of established conventional scintigraphic imaging modalities with 18F-fluorocholine PET/CT imaging in preoperative localization of hyperfunctioning parathyroid glands in patients with primary hyperparathyroidism.

Page 577

11C-Choline PET in hyperparathyroidism: Liu and colleagues assess the value of 11C-choline PET in patients with primary hyperparathyroidism and negative or discordant results on 99mTc-sestamibi imaging and neck ultrasound.

Page 584

18F-FDG inflammation imaging after aortic constriction: Glasenapp and colleagues determine whether inflammation can be serially imaged with 18F-FDG PET in early stages of pressure-overload–induced heart failure and compare the time course with functional impairment assessed by cardiac MRI.

Page 590

Prediction of conversion to AD: Blazhenets and colleagues examine the predictive values of amyloid PET, 18F-FDG PET, and nonimaging predictors (alone and in combination) for development of Alzheimer dementia in a large population of patients with mild cognitive impairment.

Page 597

TSPO versus P2X7 for neuroinflammation: Van Weehaeghe and colleagues compare imaging with 18F-DPA714, a second-generation translocator protein tracer, with 11C-JNJ717, a novel P2X7 receptor tracer, in vitro and in vivo in amyotrophic lateral sclerosis.

Page 604

Dose–response in 166Ho radioembolization: Bastiaannet and colleagues investigate the absorbed dose–response relationship and its association with overall survival for 166Ho-microsphere radioembolization in patients with liver metastases.

Page 608

Oral administration of 18F-FDG: Srinivasan and colleagues compare human biodistribution and dosimetry for 18F-FDG after sequential oral and intravenous administrations in the same subjects to determine dosimetry and potential suitability of oral 18F-FDG as an alternative to intravenous administration.

Page 613

  • © 2020 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (4)
Journal of Nuclear Medicine
Vol. 61, Issue 4
April 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Apr 2020, 61 (4) 10A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Apr 2020, 61 (4) 10A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • 18F-Fluorocholine PET/CT in Primary Hyperparathyroidism: Superior Diagnostic Performance to Conventional Scintigraphic Imaging for Localization of Hyperfunctioning Parathyroid Glands
  • TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study
  • Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management
  • Comparison of 3 Interpretation Criteria for 68Ga-PSMA11 PET Based on Inter- and Intrareader Agreement
  • First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
  • Preoperative Localization of Adenomas in Primary Hyperparathyroidism: The Value of 11C-Choline PET/CT in Patients with Negative or Discordant Findings on Ultrasonography and 99mTc-Sestamibi SPECT/CT
  • PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes
  • Introduction to Radiomics
  • Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
  • First Evidence for a Dose–Response Relationship in Patients Treated with 166Ho Radioembolization: A Prospective Study
  • A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope
  • Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer
  • Patient Travel Concerns After Treatment with 177Lu-DOTATATE
  • Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
  • Diagnostic Accuracy of PET Tracers for the Differentiation of Tumor Progression from Treatment-Related Changes in High-Grade Glioma: A Systematic Review and Metaanalysis
  • Multimodality Imaging of Inflammation and Ventricular Remodeling in Pressure-Overload Heart Failure
  • Human Radiation Dosimetry for Orally and Intravenously Administered 18F-FDG
  • Predictive Value of 18F-Florbetapir and 18F-FDG PET for Conversion from Mild Cognitive Impairment to Alzheimer Dementia
  • The Academic NDA: Justification, Process, and Lessons Learned
  • 18F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience
  • Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire